MarketBeat
13 Nov 2026, 04:15 UTC · 1h ago
What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
Impact · against what's priced in
Nektar Therapeutics gains a modest positive catalyst from the initiation of three Phase III studies for REZPEG in atopic dermatitis and the acceleration of its alopecia study. While the 2029 BLA target indicates a long road to commercialization, the raised cash outlook provides a runway that extends into 2029, reducing immediate financing risk.
- NKTR+0.40
No priced-in read yet
- In context
The company initiated three Phase III studies for REZPEG in atopic dermatitis with a 2029 BLA target and accelerated its pivotal alopecia study to December. A raised year-end cash outlook of over $840 million secures the runway through the high-burn enrollment phases.
Read from the article alone
